Currently, there are 131.16M common shares owned by the public and among those 51.97M shares have been available to trade.
The company’s stock has a 5-day price change of -0.37% and -55.35% over the past three months. PRME shares are trading -54.28% year to date (YTD), with the 12-month market performance down to -80.25% lower. It has a 12-month low price of $1.12 and touched a high of $8.27 over the same period. PRME has an average intraday trading volume of 1.52 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -11.78%, -16.94%, and -55.48% respectively.
Institutional ownership of Prime Medicine Inc (NASDAQ: PRME) shares accounts for 28.62% of the company’s 131.16M shares outstanding.
It has a market capitalization of $175.28M and a beta (3y monthly) value of 1.75. The earnings-per-share (ttm) stands at -$1.66. Price movements for the stock have been influenced by the stock’s volatility, which stands at 13.92% over the week and 13.70% over the month.
Analysts forecast that Prime Medicine Inc (PRME) will achieve an EPS of -0.33 for the current quarter, -0.29 for the next quarter and -0.93 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.42 while analysts give the company a high EPS estimate of -0.42. Comparatively, EPS for the current quarter was -0.46 a year ago. Earnings per share for the fiscal year are expected to increase by 22.79%, and 18.30% over the next financial year. EPS should grow at an annualized rate of 15.28% over the next five years, compared to -124.13% over the past 5-year period.
Looking at the support for the PRME, a number of firms have released research notes about the stock. JMP Securities stated their Mkt Outperform rating for the stock in a research note on December 10, 2024, with the firm’s price target at $10. H.C. Wainwright coverage for the Prime Medicine Inc (PRME) stock in a research note released on May 20, 2024 offered a Buy rating with a price target of $10. Citigroup was of a view on May 16, 2024 that the stock is Buy, while Chardan Capital Markets gave the stock Buy rating on April 22, 2024, issuing a price target of $17. TD Cowen on their part issued Buy rating on April 08, 2024.
